{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T08:48:44Z","timestamp":1777798124982,"version":"3.51.4"},"reference-count":13,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,7,19]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>A man in his early 40s was receiving treatment for rectal cancer with dostarlimab, an immune checkpoint inhibitor (ICI), when he developed fevers, headache and nausea. He was hospitalised with elevated liver enzymes and infectious work-up revealed an acute cytomegalovirus (CMV) infection. With concern that his dostarlimab therapy could be contributing to his inflammatory response as an ICI-induced hepatitis, the patient underwent a liver biopsy. Pathology was instead consistent with CMV hepatitis, and the patient was treated with antiviral therapy and had complete resolution of his illness. This case illustrates the importance of monitoring for immune-related adverse effects in patients taking ICIs, while still maintaining a broad differential diagnosis for other causes.<\/jats:p>","DOI":"10.1136\/bcr-2025-265250","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T07:25:16Z","timestamp":1755069916000},"page":"e265250","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Cytomegalovirus hepatitis after treatment with dostarlimab for colorectal cancer"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-7667","authenticated-orcid":false,"given":"Haleigh","family":"Harper","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Newman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The University of Kansas Medical Center, Kansas City, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The University of Kansas Medical Center, Kansas City, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"MacKenzie","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The University of Kansas Medical Center, Kansas City, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2025081300251148000_18.8.e265250.1","first-page":"83","article-title":"Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review","volume":"2","author":"Taherian","year":"2022","journal-title":"J Clin Transl Pathol"},{"key":"2025081300251148000_18.8.e265250.2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cam4.4393","article-title":"Infectious complications of immune checkpoint inhibitors in solid organ malignancies","volume":"11","author":"Ross","year":"2022","journal-title":"Cancer Med"},{"key":"2025081300251148000_18.8.e265250.3","unstructured":"FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer. 2021. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-endometrial-cancer"},{"key":"2025081300251148000_18.8.e265250.4","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000081"},{"key":"2025081300251148000_18.8.e265250.5","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/imj.15496","article-title":"Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation","volume":"52","author":"Tay","year":"2022","journal-title":"Intern Med J"},{"key":"2025081300251148000_18.8.e265250.6","first-page":"522","article-title":"Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors","volume":"35","author":"Panneerselvam","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"2025081300251148000_18.8.e265250.7","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.655"},{"key":"2025081300251148000_18.8.e265250.8","unstructured":"About Cytomegalovirus (CMV) Centers for Disease Control and Prevention. 2020. Available: https:\/\/www.cdc.gov\/cmv\/overview.html"},{"key":"2025081300251148000_18.8.e265250.9","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0. 2017. Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"2025081300251148000_18.8.e265250.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025081300251148000_18.8.e265250.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00653-1"},{"key":"2025081300251148000_18.8.e265250.12","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac570","article-title":"Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive","volume":"9","author":"Gudiol","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025081300251148000_18.8.e265250.13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-021-00824-3","article-title":"Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"16","author":"Petrelli","year":"2021","journal-title":"Target Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-265250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T07:25:18Z","timestamp":1755069918000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-265250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":13,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bcr-2025-265250"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-265250","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}